Susquehanna International Group
TRDA icon

Susquehanna International Group’s Entrada Therapeutics TRDA Stock Holding History

Susquehanna International Group’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,000
Closed -$81.2K – 13640
2025
Q3 		$81.2K Buy
+14,000
New +$81.9K ﹤0.01% 11674
2024
Q4 		– Sell
-11,300
Closed -$181K – 13240
2024
Q3 		$181K Buy
+11,300
New +$178K ﹤0.01% 10564

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group's TRDA Position: Q1 2026 in Review

Susquehanna International Group increased its Entrada Therapeutics (TRDA) stake by 32% in Q1 2026, buying an estimated $56.8K and bringing the position to 20,315 shares worth $256K. The position accounts for ﹤0.01% of the portfolio, ranked #11215.

Susquehanna International Group first reported a position in TRDA in Q4 2022 and has held it in 8 quarters since. The position peaked at $2.85M in Q1 2023. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • Susquehanna International Group held 20,315 shares of Entrada Therapeutics worth $256K as of Q1 2026.
  • Susquehanna International Group bought 4,954 Entrada Therapeutics shares in Q1 2026, an estimated $56.8K.
  • Entrada Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #11215 holding.
  • Susquehanna International Group first reported a position in Entrada Therapeutics in Q4 2022 and has held it in 8 quarters since.
  • Susquehanna International Group's Entrada Therapeutics position peaked at $2.85M in Q1 2023.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.